St. Jude Expects Easy Enrollment In New PFO Study For Migraines
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical expects the trial of its Premere patent foramen ovale (PFO) closure device in migraine patients to enroll patients faster than trials of PFO closure to prevent stroke
You may also be interested in...
MIST Trial Reveals Mixed Results For PFO Treatment Of Migraine
Preliminary clinical trial data show NMT Medical's STARflex patent foramen ovale (PFO) closure device to be no more effective than placebo in completely eliminating migraine headaches, although the device did appear to improve some symptoms
MIST Trial Reveals Mixed Results For PFO Treatment Of Migraine
Preliminary clinical trial data show NMT Medical's STARflex patent foramen ovale (PFO) closure device to be no more effective than placebo in completely eliminating migraine headaches, although the device did appear to improve some symptoms
Leading Neurologist Remains Skeptical In Run-Up To NMT’s MIST Trial Results
The soon-to-be-released results of NMT's patent foramen ovale (PFO) closure trial will need to demonstrate a 30% difference in frequency of migraine between the treatment group and the placebo group to be clinically relevant, according to a leading neurologist